Australia Considers Identifying Drugs Filed For Approval
Executive Summary
The Therapeutic Goods Administration wants to know whether, and how, it should disclose the fact that a medicine has been accepted for regulatory review. It has put several options to stakeholders, including disclosure for all medicines or only certain kinds, or keeping the current practice of “neither confirm nor deny.”
You may also be interested in...
Canada Consults On Disclosing Names Of Generic Drug Applicants
Health Canada currently does not disclose the names of the companies that have filed abbreviated new drug submissions and it wants to know what the possible impacts of doing so are.
New Canadian Transparency Drive To Facilitate Better Planning For Industry
Health Canada is making its decision-making process in the pre-market phase more transparent by disclosing a wider range of information on new and generic drug applications accepted for review.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.